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  ARTIFICIAL INTELLIGENCE IN PHARMA-
CEUTICAL PRODUCT FORMULATION: 
NEURAL COMPUTING* 
The properties of a formulation are determined not only by the ratios in which 
the ingredients are combined but also by the processing conditions. Although 
the relationships between the ingredient levels, processing conditions, and 
product performance may be known anecdotally, they can rarely be quantified. 
In the past, formulators tended to use statistical techniques to model their for-
mulations, relying on response surfaces to provide a mechanism for optimaza-
tion. However, the optimization by such a method can be misleading, espe-
cially if the formulation is complex. More recently, advances in mathematics 
and computer science have led to the development of alternative modeling and 
data mining techniques which work with a wider range of data sources: neural 
networks (an attempt to mimic the processing of the human brain); genetic al-
gorithms (an attempt to mimic the evolutionary process by which biological 
systems self-organize and adapt), and fuzzy logic (an attempt to mimic the abi-
lity of the human brain to draw conclusions and generate responses based on 
incomplete or imprecise information). In this review the current technology will 
be examined, as well as its application in pharmaceutical formulation and pro-
cessing. The challenges, benefits and future possibilities of neural computing 
will be discussed. 
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The development of a commercial product, 
whether it is a relatively simple formulation (e.g. a 
capsule, tablet or oral liquid) or a controlled release 
formulation (e.g. an implant), is always a time-con-
suming and complicated process. Generally an initial 
formulation consisting of one or more drugs mixed 
with various ingredients (excipients) is prepared, and, 
as development progresses, the choice of these and 
their levels, as well as the manufacturing process, are 
changed and optimized as a result of intensive, time-
consuming experimentation. These iterations, in turn, 
result in the generation of large amounts of data, the 
processing and understanding of which is challeng-
ing. In reality, the formulator has to work in a design 
space that is multi-dimensional and virtually impos-
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sible to conceptualize. To date, statistics has been 
used as one approach to this problem. This method 
has the advantage of generating clearly expressed 
models with associated confidence factors. However, 
for more than three or four inputs, statistical ap-
proaches rapidly become unwieldy, so that the for-
mulator is tempted to oversimplify the problem (for ex-
ample, restricting a study to three input variables) in 
order to model it. Statistics also often require the as-
sumption of a functional form (for example, linearity) 
in order to generate a model and such assumptions 
can be inappropriate for complex tasks like formu-
lation. 
In recent years, it has been shown that neural 
networks can provide an alternative approach [1]. 
Neural networks are mathematical constructs that are 
capable of “learning” relationships within data, with no 
prior knowledge required from the user. The neural 
network makes no assumptions about the functional 
form of the relationships; it simply generates and 
assesses a range of models to determine one that will 
best fit the experimental data provided to it. As such, 
increasingly, artificial neural networks (often referred 
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to as ANNs) are used to model a complex behavior in 
problems like pharmaceuticals formulation and pro-
cessing. 
The models generated by neural networks allow 
“what if” possibilities to be investigated easily. How-
ever, their capabilities are enhanced substantially by 
combining them with other technologies. For exam-
ple, using genetic algorithms for optimization, to-
gether with neural networks models, has proved to be 
exceptionally powerful when the formulator must de-
velop a formulation to meet stringent, often conflict-
ing, objectives. The objectives for the optimization 
can easily and intuitively be defined using another ar-
tificial intelligence technology, fuzzy logic. Fuzzy logic 
has proved to be especially valuable when conflicting 
properties (for example, hard tablets that disintegrate 
quickly) are desired. More recently, efforts have been 
made to integrate the technologies even more tightly, 
creating new methodologies like neurofuzzy logic, 
which combines the ability of neural networks to 
“learn” from data, with fuzzy logic’s capacity to ex-
press complex concepts in a simple fashion. These 
techniques are capable of “mining” the information 
directly from data, presenting it in the form of easy to 
understand, actionable rules that can guide the for-
mulator’s future work. 
NEURAL NETWORKS 
Like humans, neural networks learn directly from 
input data. The learning algorithms take two main 
forms. Unsupervised learning, where the network is 
presented with input data and learns to recognize pat-
terns in the data, is useful for organizing amounts of 
data into a smaller number of clusters. For supervised 
learning, which is analogous to “teaching” the net-
work, the network is presented with a series of match-
ing input and output examples, and it learns the re-
lationships connecting the inputs to the outputs. Su-
pervised learning has proved most useful for the for-
mulation, where the goal is to determine cause-and-
effect links between inputs (ingredients and process-
sing conditions) and outputs (measured properties). 
The basic component of the neural network is 
the neuron, a simple mathematical processing unit 
that takes one or more inputs and produces an out-
put. For each neuron, every input has an associated 
weight that defines its relative importance, and the 
neuron simply computes the weighted sum of all the 
outputs and calculates an output. This is then mo-
dified by means of a transformation function (some-
times called a transfer or activation function) before 
being forwarded to another neuron. This simple pro-
cessing unit is known as a perceptron, a feed-forward 
system in which the transfer of data is in the forward 
direction, from inputs to outputs, only. A neural net-
work consists of many neurons organized into a struc-
ture called the network architecture. Although there 
are many possible network architectures, one of the 
most popular and successful is the multilayer percep-
tron (MLP) network. This consists of identical neurons 
all interconnected and organized in layers, with those 
in one layer connected to those in the next layer so 
that the outputs in one layer become the inputs in the 
subsequent layer. Data flow into the network via the 
input layer, pass through one or more hidden layers, 
and finally exit via the output layer (Fig.1). In theory, 
any number of hidden layers may be added, but in 
practice multiple layers are necessary only for those 
applications with extensive nonlinear behavior, and 
they result in extended computation time. It is gene-
rally accepted that the performance of a well-design-
ed MLP model is comparable with that achieved by 
classic statistical techniques. 
Unlike conventional computer programs, which 
are explicitly programmed, supervised neural net-
works are “trained” with previous examples. The net-
work is presented with example data, and the weights 
of inputs feeding into each neuron are adjusted ite-
ratively until the output for a specific network is close 
to the desired output. The method used to adjust the 
weights is generally called back propagation, because 
the size of the error is fed back into the calculation for 
the weight changes. There are a number of possible 
back propagation algorithms, most with adjustable 
parameters designed to increase the rate and degree 
of convergence between the calculated and the de-
sired (actual) outputs. Although training can be a re-
latively slow process, especially if there are large 
amounts of data, once trained, neural networks are 
inherently fast in execution. 
FUZZY LOGIC 
Conventional logic demands that a proposition is 
either true or false. This maps onto a conventional set 
theory, so that a hypothesis lies either in the “true” 
set, or lies wholly outside it. That is, the membership 
function in the “true” set is either 1 (the hypothesis is 
true) or 0 (the hypothesis lies outside the “true” set, 
and is false). In real life, though, these black-and-white 
concepts may be of little utility. An oft-cited example 
is the definition of a comfortable room temperature. If 
a temperature of 20 °C is defined as “comfortable”, 
conventional logic would dictate that 19 or 21 °C, 
which lie outside this set, are “uncomfortable”). A very 
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complex set of rules would be required to define 
“comfortable” using conventional logic. Fuzzy logic al-
lows more intuitive statements and descriptors to be 
used, so is more akin to the linguistic format adopted 
by formulators. Fuzzy logic is based on the concept of 
fuzzy sets introduced in the 1960s by Lotfi Zadeh [2]. 
For fuzzy sets, membership functions are not res-
tricted to be 0 or 1, but can take any continuous value 
between these limits. In the context of comfortable 
room temperature, for example, a temperature of 17 
°C might have a membership of 0.4 in the “hot” set 
and 0.6 in the “cold” set, as illustrated in Figure 2. 
Fuzzy logic can be especially useful in descry-
bing target properties for optimizations. For example, 
the formulator might be seeking a tablet disintegration 
time of 300 s, i.e. any value less than 300 s has a 
desirability of 1 (i.e. 100%). But a tablet which disin-
tegrates in 310 s is not entirely undesirable (as crisp 
logic would insist), and instead might be assigned a 
desirability value of 0.9. 
Fuzzy logic is also widely used in the area of 
process control, because it allows rules to be expres-
sed in a simple linguistic form IF (A) THEN (B) with an 
associated confidence function that is related to the 
 
Figure 1. Diagram of a multilayer perceptron with one hidden layer. 
 
Figure 2. Fuzzy logic representation of room temperature. 
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set membership. To understand how this is used for 
the process control, consider a simple example of a 
fan heater governed by 4 rules, summarized in Figure 
3. These rules map onto the four fuzzy sets COLD, 
COOL, WARM and HOT. So, for example, if the room 
temperature is 18 °C, then by Rule 2 the fan speed is 
medium, with truth level 0.7, and by Rule 3 the fan 
speed is low, with truth level 0.3. The process of de-
fuzzification then allows the correct and smooth ad-
justment of the fan speed. 
NEUROFUZZY LOGIC 
Because fuzzy logic allows objectives to be ex-
pressed in simple terms, it complements neural net-
work modelling. In the case of neurofuzzy logic, as 
the name suggests, the fuzzy logic is tightly coupled 
with a neural network. 
Neurofuzzy logic combines the ability of neural 
networks to learn from data with fuzzy logic’s ability to 
express complex concepts intuitively. This creates a 
degree of transparency for the otherwise “black box” 
neural network models, leading to the term “grey box 
modelling” being applied for these methods. Neuro-
fuzzy logic has proved to be exceptionally suited to 
data mining, since it not only can develop good mo-
dels from data, but it also has the capability of expres-
sing these as linguistic IF…THEN rules. 
The neurofuzzy architecture is in essence a 
neural network with two additional layers for fuzzifi-
cation of inputs and defuzzification of outputs [3]. The 
modeling capabilities of neurofuzzy systems depend 
on the number, shape and distribution of the fuzzy 
membership input functions. In the simplest case, 
only two, LOW and HIGH would suffice. In some 
cases, it is appropriate to add more; for example, a 
problem showing a quadratic dependency would re-
quire at least LOW, MEDIUM and HIGH in order that 
it be properly represented. Where data are scarce, 
relatively few membership functions should be used. 
As the number and complexity of the inputs in-
creases, the rules become more complicated, and 
this can make them difficult to understand. 
EVOLUTIONARY COMPUTING 
Evolutionary computing is a general term that 
describes computational processes in which solutions 
evolve, using rules of inheritance, recombination (or 
cross-over), mutation and selection. One particular 
subset of this, evolutionary algorithms, has found the 
application in the formulation research.  
GENETIC ALGORITHMS 
Genetic algorithms were pioneered in the 1970s 
by John Holland [4]. They provide a search technique 
which is particularly suited to optimization; a trial po-
pulation is assumed, and this evolves in an iterative 
process. During this process, an initial population of 
solutions is generated, and the fitness of each mem-
ber of the population is assessed. The fittest solutions 
then become the “parents” of the next generation. 
Allowing some recombination and mutation introdu-
ces a further degree of novelty into the population so 
that the genetic algorithm is more likely to find a glo-
bal optimum solution. It is this ability to find the global 
optimum in a complex design space which renders 
 
Figure 3. Fuzzy logic for process control of room temperature. 
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genetic algorithms so useful, especially when com-
pared with more directed searches like conjugate gra-
dient and steepest descent methods. 
One requirement for genetic algorithms is that a 
criterion of “fitness” can be defined. This can vary 
from problem to problem. For multi-dimensional opti-
mization, it has proved useful to define an objective 
function which is a weighted sum of the desirability of 
each of the properties. The use of weights in the sum 
allows some properties to assume more importance 
than others, and the fittest solutions are those that 
best meet the overall objectives. 
In defining the desired values of the properties, 
fuzzy logic (discussed previously) provides a useful 
framework. Two typical desirability functions are shown 
in Figure 4. One is for the case where disintegration 
time of a tablet is most desirable below 240 s, and 
completely undesirable above 360 s. The second is 
for the case where the disintegration time should lie 
between 240 and 360 s, becoming progressively less 
desirable as it moves farther away from this region. 
Genetic programming, generally regarded as a 
subset of genetic algorithms, is the most recent of the 
techniques reviewed here, having been widely popu-
larized only in the 1990s primarily by Koza [5]. As yet, 
it has had a limited use in pharmaceutical formulation, 
but it shows great promise since it has the learning 
capabilities similar to that of neural networks but the 
transparency associated with a straightforward ma-
thematical expression. In genetic programming, each 
solution is a “tree”, in which each tree node has an 
operator function and each terminal node is an ope-
rand. These trees provide an alternative way of re-
presenting equations; Figure 5 shows one such ex-
ample. An initial population of solutions is assumed, 
and as with other evolutionary methods, the fitness of 
 
Figure 4. Desirability functions for tablet disintegration time (a) below 240 s and (b) between 240 and 360 s. 
 
Figure 5. Genetic programming tree representation of equation. 
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each member is assessed. The population then evol-
ves allowing crossover (whereby parts of trees are 
swapped) and mutation; these operations are illus-
trated in Figure 6. The evolution is biased so that the 
fittest solutions are emphasized in successive gene-
rations, leading to increased improvement in the fit of 
the model to the training data. 
In the same way as for other genetic algorithms, 
a criterion of fitness needs to be defined. The simp-
lest criterion would simply minimize the mean-squar-
ed error between the calculated and actual values, 
but this could result in an overly complex, and poten-
tially over-fitted, model. Therefore, it is often appro-
priate to use a model assessment criterion (such as 
structural risk minimization) to penalize those solu-
tions whose added complexity does not return signi-
ficant new knowledge. 
Genetic programming currently suffers from the 
disadvantage that it is time consuming, and its appli-
cation is less well understood in the formulation do-
main than are neural networks. Nonetheless they are 
attractive possibilities for future work, because they 
can produce “transparent” models. 
INTEGRATED SOFTWARE 
The technologies described above are well suit-
ed to data mining and modelling, but in their raw form 
require a degree of expertise. To be truly useful to 
product formulators, the technologies described above 
need to be integrated into packages that use sensible 
default values for the parameters, and that incorpo-
rate all of the essential tools. For example, to develop 
a package aimed at producing optimized formula-
tions, the modelling capability of neural networks 
combines well with the optimization provided by ge-
netic algorithms. As discussed above, fuzzy logic 
complements this by providing a useful framework for 
defining the objectives for the optimization in a clear 
and intuitive way. 
In addition to the specific neural and evolutio-
nary technologies, it is useful also to integrate some 
basic statistics (both for examining the data and for 
assessing the quality of the models, using ANOVA 
Analysis of Variance, statistics), to provide a visuali-
zation capability. Such integrated packages are now 
available commercially and are proving useful in the 
pharmaceutical industry. An early exemplar of this is 
CAD/Chem [6]; more recently, since CAD/Chem is no 
 
Figure 6. Crossover (a) and mutation (b) for genetic programming trees. 
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longer available, INForm from Intelligensys has been 
developed. A data mining package based on neuro-
fuzzy logic, FormRules, is also commercially availab-
le, with integrated visualization as well as statistical 
techniques to assess the quality of models. 
APPLICATIONS 
Over the past fifteen years the technology des-
cribed above has been used extensively to model and 
optimize formulations from simple to very complex. It 
has also been used to a lesser degree in pharma-
ceutical processing. 
Oral formulations – immediate release 
The earliest study in this field was reported by 
Turkoglu et al. [7] who modeled a direct compression 
tablet formulation containing hydrochlorothiazide in 
order to maximize tablet strength and select the best 
lubricant. In another study, Kesavan and Peck [8] mo-
deled a tablet formulation of caffeine in order to relate 
both formulation (diluent type and concentration, bin-
der concentration) and processing variables (type of 
granulator, method of addition of binder) with granule 
and tablet properties (friability, hardness, and disinter-
gration time). Both these investigations showed that 
neural networks performed better than conventional 
statistical methods. Subsequently, the data of Kesa-
van and Peck were reanalyzed using a combination 
of neural networks and genetic algorithms [9]. This 
showed that the optimum formulation depended both 
on the relative importance placed on the output pro-
perties and on the constraints applied both to the le-
vels of the ingredients and to the processing variab-
les. Many optimum formulations could be produced, 
depending on the “trade-offs” that could be accepted 
for different aspects of product performance. The 
same data have been studied using neurofuzzy com-
puting [10]. Useful rules were automatically gene-
rated, highlighting the most important factors for each 
property and their interdependencies. As expected, 
the rules for friability are the inverse of those for tablet 
hardness, while the rules for disintegration time in-
volved the diluent itself, the binder concentration, the 
method of addition of binder (wet or dry) and the me-
thod of granulation. 
In a series of papers, Bourquin et al. [11–14] 
highlighted the advantages and disadvantages of 
neural networks in formulating the immediate release 
tablets. The data generated by these authors have 
been used by Plumb et al. [15] to compare three dif-
ferent neural network programs and four classes of 
training algorithms in terms of capability of generating 
predictive models. They found that the most predict-
tive models from each neural network varied with res-
pect to the optimum network architecture and training 
algorithm. No significant differences were found in the 
predictive ability of these models.  
Recently, the same data have been analysed by 
Shao et al. [16] who compared neurofuzzy techniques 
with neural networks. They found that neurofuzzy me-
thods developed models that were almost as good as 
neural networks (as determined using analysis of va-
riance statistics). However, the neurofuzzy results 
had the advantage that they also generated rules that 
were presented in a simple understandable format. 
Rocksloh et al. [17] used neural networks suc-
cessfully to optimize the crushing strength and disin-
tegration time of a high-dose plant extract tablet. In 
another study using both neural networks and genetic 
algorithms, Do et al. [18] showed the advantages of 
combining these technologies in the formulation of 
antacid tablets. Chen et al. [19] used neural networks 
to predict the drug content and hardness of intact 
tablets of ophylline mixed with microcrystalline cellu-
lose from their near-infrared spectra. The model pro-
ved better than a statistical model generated with the 
same data. The superiority of neural network models 
over statistical models has also been found by Sathe 
and Venitz [20] this time for predicting the dissolution 
of 28 diltiazem immediate release tablet formulations. 
In a recent paper, Lindberg and Colbourn [21] work-
ing in Sweden and the UK used neural networks, ge-
netic algorithms and neurofuzzy to analyze historical 
data from three different immediate release formula-
tions. In all cases, the models generated performed 
satisfactorily in producing tablets with specific desired 
properties. 
Apart from immediate release tablet formula-
tions, neural networks have also been applied to mo-
delling the immediate release capsule formulations 
[22], rapidly disintegrating or dissolving tablets [23] 
and a novel oral microemulsion formulation of rifamy-
cin and isoniazid for the treatment of children during 
the continuation phase of tuberculosis [24]. Solid dis-
persion formulations of ketoprofen have recently been 
modelled using both neural networks and neurofuzzy 
with good predictability [25]. The study has also been 
extended by the addition of a microemulsion formu-
lation [26]. 
In a detailed evaluation of both neural networks 
and guided evolutionary simulated annealing for the 
modeling and optimization of a tablet coating formu-
lation, Plumb et al. [27,28] concluded that, for conflict-
ing properties such as crack propagation and film 
opacity that displayed highly curved responses with 
respect to the formulation inputs (e.g. pigment particle 
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size, pigment concentration and film thickness), clas-
sical experimental designs to map the experimental 
space are inappropriate for neural network modeling. 
However, if a pseudo-random design was used, it 
was possible to model and optimize the film coating, 
predicting formulations that were either crack resis-
tant or that were fully opaque. Similar formulations 
have also been studied using neurofuzzy computing 
[29], where rules were generated relating both the 
opacity and crack resistance to the input variables. In 
line with expectations, the technique discovered for 
itself that for maximum opacity the films needed to be 
thick with a high pigment concentration and a small 
pigment size. 
Controlled release oral formulations 
Chen et al. [30] used an artificial neural network 
(ANN) and pharmacokinetic simulations in the design 
of controlled-release formulations. Seven formulation 
variables and three other tablet variables (moisture, 
particle size and hardness) for 22 tablet formulations 
of a model drug were used as the ANN model inputs. 
In vitro cumulative percentage of drug released at 10 
different sampling time points were used as outputs. 
The ANN model was developed and trained from the 
input and the output data sets using CAD/Chem soft-
ware. The trained ANN model was used to predict 
optimal formulation compositions based on two desi-
red in vitro dissolution-time profiles and two desired in 
vivo release profiles. The authors assumed that the 
dissolution is the rate-limiting step in the in vivo ab-
sorption of the drug that the fraction of the drug ab-
sorbed in vivo is linearly related to the in vitro disso-
lution of the drug. Three out of four predicted formula-
tions showed very good agreement between the ANN 
predicted and the observed in vitro release profiles 
based on difference factor, f1, and similarity factor, f2. 
Zupančić Božić et al. [31] developed an ANN 
model to optimize diclofenac sodium sustained re-
lease matrix tablets. Formulation variables including 
concentrations of cetyl alcohol, polyvinylpyrolidone K 
30 and magnesium stearate, and sampling time were 
chosen as inputs. Twelve hidden nodes were inclu-
ded in the hidden layer. The percentage of the drug 
released at each sampliing time point was used as 
the output. A trained ANN model was employed to 
predict release profile and optimize the formulation 
composition based on the percentage of the drug re-
leased. 
Tokayama et al. [32] developed a simultaneous 
optimization technique in which the ANN model was 
used to optimize controlled release theophylline tab-
lets prepared with controse, the mixture of hydroxy-
propylmethyl cellulose with lactose and cornstarch. 
The release profiles of theophylline were characte-
rized as the sum of the fast and slow release frac-
tions. To build the ANN model, the amounts of con-
trose, cornstarch and compression pressure were se-
lected as causal factors; the initial weight of theophyl-
line, the rate constant in the fast release fraction and 
the release rate constant in the slow release fraction 
were chosen as response variables. The results pre-
dicted by the trained ANN model agreed well with the 
observed values. Assuming that the release rate of 
theophylline in the GI tract is equal to the absorption 
rate, the rate constant in the fast release fraction and 
the release rate constant in the slow release fraction 
were used as absorption rate constants. The plasma 
concentrations profiles were simulated based on the 
simulated plasma concentration profiles. The optima-
zation of the controlled release theophylline tablets 
was performed by a generalized distanced function 
method using the optimal release parameters. 
A generalized regression neural network (GRNN) 
was used in the design of extended-release aspirin 
tablets by Ibric et al. [33,34]. Ten aspirin matrix tablet 
model formulations were prepared with Eudrgit RS 
PO [33]. The amount of Eudragit RS PO and com-
pression pressure were selected as causal factors. In 
vitro dissolution-time profiles at four different samp-
ling time points, as well as coefficients n (release 
order) and log k (release constant) from the Peppas 
equation were estimated as release parameters. A 
set of release parameters and causal factors were 
used for training. The optimized GRNN model was 
used to predict the formulation and process factors for 
the optimized formulations, which would give the de-
sired in vitro drug release profiles. The two optimized 
formulations were then prepared and tested in vitro. 
The comparison between the GRNN predicted and 
observed in vitro profiles, and estimated coefficients 
indicated that there is no difference between the pre-
dicted and experimentally observed drug release pro-
files for the two tested formulations based on the dif-
ference factor, f1 and similarity factor, f2. The same 
authors applied GRNN for predicting the drug stabi-
lity, and in vitro–in vivo correlation [35,36]. 
In coated tablets, the controlling mechanism for 
drug release is generally the film applied to the tablet, 
although in some circumstances the release may be 
controlled in addition by the tablet core formulation. In 
a detailed study of 125 formulations for small tablets 
prepared from a model drug embedded in a hydro-
philic matrix and then coated with an enteric polymer, 
Leane et al. [37] were able to apply various input fea-
ture selection algorithms, including genetic algo-
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rithms, to evaluate the relative importance of the input 
variables. They then used a neural network to model 
subsets of the data, with the less significant inputs 
eliminated. As expected, the elimination of the less 
significant inputs results in more generalized predict-
tive models. In another study, Wu et al. [38] used a 
neural network to model the formulation of salbutanol 
sulfate osmotic pump tablets, using the amount of 
hydroxypropyl methyl cellulose and polyethylene gly-
col present in the cellulose acetate coating, in addi-
tion to the coating weight, as control factors. Using 
the model, the authors predicted the release parame-
ters for 1000 formulations, from which they selected 
an optimum with the desired release pattern. 
In pelleted or multi-particulate formulations, the 
drug release mechanism can be controlled either by 
using a rate controlling matrix or by the use of films. 
The pellets are either produced by using extrusion 
and spheronization or by layering onto sugar cores. In 
some cases, the pellets may be tabletted. In others, 
they are packed into hard gelatin capsules. Peh et al. 
[39,40] applied both multi-layer perceptrons  and re-
current neural networks [41] to model successfully the 
release of theophylline from a matrix controlled re-
lease pellet formulation prepared using extrusion and 
spheronization. In another study on pellets, this time 
prepared using the layering technique followed by 
polymer film coating, Vaithiyalingam et al. [42] com-
pared the modelling and optimization abilities of sim-
plex and neural network procedures. They concluded 
that from very limited data sets, simplex optimization 
was more appropriate although neural networks were 
“a valuable and predictive tool”. In a follow-up study, 
Vaithiyalingam and Khan [43] compared a response 
surface methodology and neural networks for model-
ling and optimizing the effect of the process and for-
mulation variables on the release profile of verapamil 
hydrochloride. In each case, the observed drug re-
lease profile of the optimized formulation was close to 
that predicted from the model. In another study, flui-
dized bed manufactured, enteric-coated, omeprazole 
pellets compressed into tablets were analyzed using 
neural networks [44]. From the model, the authors 
were able to predict a positive correlation between the 
tablet strength and the concentration of the microcrys-
talline cellulose used as a compression aid. However, 
the degradation of the omeprazole in such media was 
also dependent on the microcrystalline cellulose con-
centration. 
A bimodal drug delivery system consisting of 
pellets coated with pectin and chitosan has recently 
been modeled using neural networkswith five different 
training algorithms [45]. The authors concluded that 
those networks trained using gradient descent back-
propagation algorithms outperformed the others. The 
textural properties of a novel pellet formulation ca-
pable of extensive gelation and swelling in biological 
fluids, coined “gelisphere” by its inventor, have been 
modeled by Pillay and Danckwerts [46] using both 
statistics and neural networks. The authors concluded 
that neural networks were a more reliable data pre-
dictor in the design of their system. 
BENEFITS AND ISSUES 
Although there is a great deal of interest in neu-
ral computing, the quantified information on the bene-
fits has been harder to find. From the applications 
described above, benefits that could be seen included: 
– effective use of incomplete data sets, 
– rapid analysis of data, 
– ability to accommodate more data and retrain 
the network (refine the model), 
– effective exploration of the total design space, 
irrespective of complexity, 
– ability to accommodate constraints and prefe-
rences and 
– ability to generate understandable rules. 
In a survey [47] on the use of 93 neural com-
puting applications in 75 UK companies covering all 
business sectors, the major benefits identified were 
the improved quality, improved response times, and 
increased productivity. Eighty-four percent of users 
were satisfied or very satisfied with their systems with 
only three percent expressing dissatisfaction. Busi-
ness benefits, specifically for the domain of product 
formulation (albeit for nonpharmaceuticals), have 
been given as [48]: 
– enhancement of product quality and perfor–
mance at low cost, 
– shorter time to market, 
– development of new products, 
– improved customer response, 
– improved confidence and 
– improved competitive edge. 
As this new technology moves from the realm of 
academe into practical application, there are also is-
sues regarding the implementation of neural com-
puting. Users in the previously cited study were asked 
to identify where they had experienced problems. 
Thirty-nine percent had found problems related to 
software and lack of development skills; this will be 
reduced as commercial packages come into wider 
use and there is less need for bespoke in-house sys-
tems with their high programming and maintenance 
burden. 
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However, even when commercial packages are 
used, there are a number of features that should be 
present before neural computing can be used to ad-
vantage. The problem must be numeric in nature, and 
reasonable quantities of data should be available to 
train an adequate model. The greatest benefits are 
achieved for multidimensional problems where it is 
difficult to express any analytic model and difficult to 
abstract the rules by any other mechanism than neu-
ral computing. It helps if the problem is of practical 
importance, is part of the organization’s essential 
activity, and meets a real business need. Pharmaceu-
tical formulation meets these criteria well, and neural 
computing can be expected to provide significant be-
nefits in industry in the future. 
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